Compare · AARD vs NVO
AARD vs NVO
Side-by-side comparison of Aardvark Therapeutics Inc. (AARD) and Novo Nordisk A/S (NVO): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both AARD and NVO operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NVO is the larger of the two at $173.66B, about 2055.8x AARD ($84.5M).
- Over the past year, AARD is down 70.5% and NVO is down 28.6% - NVO leads by 41.9 points.
- AARD has been more active in the news (6 items in the past 4 weeks vs 4 for NVO).
- NVO has more recent analyst coverage (25 ratings vs 16 for AARD).
- Company
- Aardvark Therapeutics Inc.
- Novo Nordisk A/S
- Price
- $3.77-3.46%
- $38.82-1.05%
- Market cap
- $84.5M
- $173.66B
- 1M return
- -32.32%
- -10.14%
- 1Y return
- -70.51%
- -28.57%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NYSE
- IPO
- 2025
- News (4w)
- 6
- 4
- Recent ratings
- 16
- 25
Novo Nordisk A/S
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson's diseases; and bluebird bio, Inc. to develop genome editing treatments for children and adult patients. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Latest AARD
- AARD UPCOMING DEADLINE: Levi & Korsinsky Alerts Aardvark Therapeutics, Inc. Stockholders of Securities Class Action - Contact the Firm
- SEC Form 4 filed by Aardvark Therapeutics Inc.
- SEC Form 3 filed by Aardvark Therapeutics Inc.
- SEC Form 8-K filed by Aardvark Therapeutics Inc.
- Aardvark Therapeutics Appoints Clinical Development Leader David Zhang, Ph.D., MBA, to its Board of Directors
- Aardvark Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
- Officer Sun Nelson sold $394,957 worth of shares (76,754 units at $5.15) as part of a pre-agreed trading plan, decreasing direct ownership by 68% to 35,475 units (SEC Form 4)
- SEC Form 4 filed by Director Chi Jeffrey
- SEC Form 4 filed by Director Graf Susan E
- SEC Form 4 filed by Director Baynes Roy D.
Latest NVO
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- Novo Nordisk A/S downgraded by Morgan Stanley with a new price target
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- Novo Nordisk A/S downgraded by Deutsche Bank